ResearcherCentre Hospitalier Universitaire de ReimsNo recent work listed
Iman El Hariry
Matched on OpenAlex author ID A5010535132. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 11
2020: 3 papers
Papers 3
- Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized … Last author DOI 10.1016/j.ejca.2019.10.020↗
- Erratum to 'Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label,… Last author DOI 10.1016/j.ejca.2020.02.004↗
- Circulating Tumor DNA is Prognostic and Potentially Predictive of Eryaspase Efficacy in Second-line in Patients with Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-20-0950↗
Closest collaborators
The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jerome F. Cros · 3 shared papers, 2020 · strength 0.27
- Paper Circulating Tumor DNA is Prognostic and Potentially Predictive of Eryaspase Efficacy in Second-line in Patients with Ad… DOI 10.1158/1078-0432.ccr-20-0950↗
- Paper Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancr… DOI 10.1016/j.ejca.2019.10.020↗
- Paper Erratum to 'Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of ad… DOI 10.1016/j.ejca.2020.02.004↗
- Fabienne Portales · 3 shared papers, 2020 · strength 0.27
- Paper Circulating Tumor DNA is Prognostic and Potentially Predictive of Eryaspase Efficacy in Second-line in Patients with Ad… DOI 10.1158/1078-0432.ccr-20-0950↗
- Paper Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancr… DOI 10.1016/j.ejca.2019.10.020↗
- Paper Erratum to 'Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of ad… DOI 10.1016/j.ejca.2020.02.004↗
- Pascal R. Hammel · 3 shared papers, 2020 · strength 0.27
- Paper Circulating Tumor DNA is Prognostic and Potentially Predictive of Eryaspase Efficacy in Second-line in Patients with Ad… DOI 10.1158/1078-0432.ccr-20-0950↗
- Paper Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancr… DOI 10.1016/j.ejca.2019.10.020↗
- Paper Erratum to 'Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of ad… DOI 10.1016/j.ejca.2020.02.004↗
- Jean‐Baptiste Bachet · 3 shared papers, 2020 · strength 0.27
- Paper Circulating Tumor DNA is Prognostic and Potentially Predictive of Eryaspase Efficacy in Second-line in Patients with Ad… DOI 10.1158/1078-0432.ccr-20-0950↗
- Paper Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancr… DOI 10.1016/j.ejca.2019.10.020↗
- Paper Erratum to 'Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of ad… DOI 10.1016/j.ejca.2020.02.004↗
- Christophe Tournigand · 2 shared papers, 2020 · strength 0.17
- Paper Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancr… DOI 10.1016/j.ejca.2019.10.020↗
- Paper Erratum to 'Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of ad… DOI 10.1016/j.ejca.2020.02.004↗
- Christelle de la Fouchardière · 2 shared papers, 2020 · strength 0.17
- Paper Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancr… DOI 10.1016/j.ejca.2019.10.020↗
- Paper Erratum to 'Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of ad… DOI 10.1016/j.ejca.2020.02.004↗
- Thierry André · 2 shared papers, 2020 · strength 0.17
- Paper Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancr… DOI 10.1016/j.ejca.2019.10.020↗
- Paper Erratum to 'Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of ad… DOI 10.1016/j.ejca.2020.02.004↗
- Christophe Louvet · 2 shared papers, 2020 · strength 0.17
- Paper Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancr… DOI 10.1016/j.ejca.2019.10.020↗
- Paper Erratum to 'Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of ad… DOI 10.1016/j.ejca.2020.02.004↗
- David Tougeron · 2 shared papers, 2020 · strength 0.17
- Paper Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancr… DOI 10.1016/j.ejca.2019.10.020↗
- Paper Erratum to 'Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of ad… DOI 10.1016/j.ejca.2020.02.004↗
- Olivier Bouché · 2 shared papers, 2020 · strength 0.17
- Paper Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancr… DOI 10.1016/j.ejca.2019.10.020↗
- Paper Erratum to 'Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of ad… DOI 10.1016/j.ejca.2020.02.004↗
- Pierre Laurent‐Puig · 1 shared paper, 2020 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.